Seek Labs, a biotech company dedicated to advancing global health through AI-driven therapeutic discovery and point-of-care diagnostics, has expanded its Global Disease Atlas™ to include comprehensive mapping of hemorrhagic fever viruses. The company’s proprietary AI-powered discovery engine, BioSeeker™, has completed detailed genomic analysis across multiple high-priority hemorrhagic fever viruses (HFVs), including Ebola virus, Marburg virus, and Lassa virus. This expansion enhances the Atlas’s ability to identify conserved genomic regions and potential therapeutic targets across diverse viral strains, enabling faster development of broad-spectrum treatments and diagnostics. By leveraging machine learning and advanced bioinformatics, BioSeeker™ can rapidly analyze vast genomic datasets to pinpoint vulnerabilities in these deadly pathogens—many of which lack effective treatments or vaccines. The updated Atlas now serves as a critical resource for researchers, public health agencies, and pharmaceutical developers working to combat outbreaks and prepare for future pandemics. With hemorrhagic fevers posing significant threats in endemic regions and the potential for global spread, the ability to accelerate discovery is more urgent than ever. Seek Labs emphasizes that the integration of AI into early-stage discovery is transforming how the world responds to emerging infectious diseases. By combining real-time genomic surveillance with predictive modeling, BioSeeker™ enables proactive identification of high-risk pathogens and accelerates the path from data to actionable solutions. The company continues to refine its platform with new data inputs and expanded viral coverage, reinforcing its mission to create a healthier world through programmable therapeutics and accessible diagnostics.